Stargardt Disease clinical trials at UC Health
2 research studies open to eligible people

  • Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

    open to eligible people ages 12-60

    The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 12 and 60 years old. Funding Source - FDA OOPD

    at UCLA

  • Safety and Efficacy of Emixustat in Stargardt Disease

    open to eligible people ages 16 years and up

    The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease.

    at UCSF

Last updated: